Nordic Nanovector and Heidelberg Pharma GmbH have entered a research agreement to develop novel treatment for leukaemia.
According to the agreement, the two partners will jointly develop novel antibody drug conjugates (ADCs) to treat leukaemia.
The agreement enables Nordic Nanovector to strengthen its product pipeline.
Myriad RBM and Sanofi have entered an agreement to analyse the cardiovascular risk in diabetic patients using biomarkers analysis.
Under the agreement, Sanofi will be responsible to provide 5,300 serum samples of patients from evaluation of Lixisenatide in acute coronary syndrome (ELIXA) trial. Myraid RBM will analyse the samples with CustomMAP platform to identify the biomarkers to predict cardiovascular and microvascular risk in diabetic patients.
Relief Therapeutics and FirstString Research have entered a partnership to further advance the clinical development of atexakin alfa in the US.
According to the agreement, FristString will gain financial support from the US Government to submit an investigational new drug (IND) application of the drug to the FDA.
The agreement allows the partners to strengthen their research and commercial relationship.
Ritter Pharmaceuticals plans for an underwritten public offering of its common stock shares. Aegis Capital is acting as a sole book running manager to the company for the offering.
The company plans to use the funds to increase the working capital and for other general corporate purposes.
Everstone Capital Management has invested $33m to acquire a 70% stake in Rubicon Research.
The company has acquired the stakes from Kotak Private Equity and another undisclosed private investor.
Rubicon Research will use the funds to accelerate its growth.